Cephalalgia最新文献_第7页

Latent class analysis of migraine associated vestibular-auditory symptoms. 偏头痛相关前庭-听觉症状的潜类分析。

IF 4.9 2区医学

Cephalalgia Pub Date : 2024-06-01 DOI: 10.1177/03331024241262488

Hui Li, Xiaonuo Xu, Rongjiang Xu, Ping Xiao Fan, Jiying Zhou, Liang Dong

{"title":"Latent class analysis of migraine associated vestibular-auditory symptoms.","authors":"Hui Li, Xiaonuo Xu, Rongjiang Xu, Ping Xiao Fan, Jiying Zhou, Liang Dong","doi":"10.1177/03331024241262488","DOIUrl":"https://doi.org/10.1177/03331024241262488","url":null,"abstract":"Objective: This study aimed to identify the potential subgroups of migraines based on the patterns of migraine associated symptoms, vestibular and auditory symptoms using latent class analysis and to explore their characteristics.Method: A total of 555 patients with migraine participated in the study. Symptoms such as nausea, vomiting, photophobia, phonophobia, osmophobia, visual symptoms, vestibular symptoms (dizziness, vertigo), and auditory symptoms (tinnitus, hearing loss, aural fullness) were assessed. Latent class analysis was performed to identify subgroups of migraines. Covariates such as gender, age of migraine onset, frequency of migraine attacks per month, and family history were also considered.Results: The analysis revealed four latent classes: the Prominent Vestibular; Prominent Nausea; Presenting Symptoms but not prominent or dominant; and Sensory Hypersensitivity groups. Various covariates, such as gender, age of migraine onset, and frequency of migraine attacks, demonstrated significant differences among the four groups. The Sensory Hypersensitivity group showed the presence of multiple sensory symptoms, earlier age of migraine onset, and higher proportion of females. The Prominent Vestibular group had the highest probability of dizziness or vertigo but lacked the presence of auditory symptoms. The Prominent Nausea group exhibited prominent nausea. The Presenting Symptoms but not prominent or dominant group comprised individuals with the highest migraine attacks per month and proportion of chronic migraine.Conclusion: This study identifies four subgroups of migraines based on the patterns of symptoms. The findings suggest potential different but overlapped mechanisms behind the vestibular and auditory symptoms of migraine. Considering the different patterns of migraine-related symptoms may provide deeper insights for patients' prognosis and clinical decision-making.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 6","pages":"3331024241262488"},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan. 100 毫克拉斯米丹治疗偏头痛的疗效和耐受性：日本多中心前瞻性真实世界观察研究。

IF 5 2区医学

Cephalalgia Pub Date : 2024-06-01 DOI: 10.1177/03331024241258695

Ryotaro Ishii, Kei Ishizuchi, Narumi Watanabe, Ryosuke Fukazawa, Meesha Trivedi, Jin Nakahara, Tsubasa Takizawa

{"title":"Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan.","authors":"Ryotaro Ishii, Kei Ishizuchi, Narumi Watanabe, Ryosuke Fukazawa, Meesha Trivedi, Jin Nakahara, Tsubasa Takizawa","doi":"10.1177/03331024241258695","DOIUrl":"10.1177/03331024241258695","url":null,"abstract":"Background: Real-world data on the effectiveness and safety of lasmiditan, a new medication for acute migraine attacks, is necessary.Methods: We performed a prospective, observational, multi-center, real-world study. A total of 48 patients with migraine (44 females, 44.6 ± 12.9 years old) were included in this study.Results: Twenty-three patients (47.9%) reported they were headache-free two hours after taking lasmiditan and were categorized into the responder group. In total, 44 patients (91.7%) experienced at least one side effect within two hours of taking the medication. Dizziness, somnolence, malaise, nausea, and palpitations were reported by 56.3% (n = 27), 45.8% (n = 22), 37.5% (n = 18), 20.8% (n = 10), and 14.6% (n = 7) of patients respectively. Of 48 patients, 20 (41.7%) indicated that they preferred lasmiditan to their previous acute treatment. There were no predictive factors for efficacy.Conclusion: This real-world study demonstrated the efficacy and safety of lasmiditan. More than 90% of patients experienced side effects from lasmiditan. Approximately 40% of patients preferred lasmiditan despite the occurrence of side effects.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 6","pages":"3331024241258695"},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acupuncture plus topiramate placebo versus topiramate plus sham acupuncture for the preventive treatment of chronic migraine: A single-blind, double-dummy, randomized controlled trial. 针灸加托吡酯安慰剂与托吡酯加假针灸对慢性偏头痛的预防性治疗：单盲双盲随机对照试验。

IF 5 2区医学

Cephalalgia Pub Date : 2024-06-01 DOI: 10.1177/03331024241261080

Lu Liu, Qiuyi Chen, Luopeng Zhao, Tianli Lyu, Limin Nie, Quan Miao, Yuhan Liu, Libin Zheng, Feiyu Fu, Yuxi Luo, Chenxi Zeng, Chengcheng Zhang, Peiyue Peng, Yixin Zhang, Bin Li

{"title":"Acupuncture plus topiramate placebo versus topiramate plus sham acupuncture for the preventive treatment of chronic migraine: A single-blind, double-dummy, randomized controlled trial.","authors":"Lu Liu, Qiuyi Chen, Luopeng Zhao, Tianli Lyu, Limin Nie, Quan Miao, Yuhan Liu, Libin Zheng, Feiyu Fu, Yuxi Luo, Chenxi Zeng, Chengcheng Zhang, Peiyue Peng, Yixin Zhang, Bin Li","doi":"10.1177/03331024241261080","DOIUrl":"10.1177/03331024241261080","url":null,"abstract":"Background: Acupuncture has been used for the treatment of chronic migraine, but high-quality evidence is scarce. We aimed to evaluate acupuncture's efficacy and safety compared to topiramate for chronic migraine.Methods: This double-dummy randomized controlled trial included participants aged 18-65 years diagnosed with chronic migraine. They were randomly assigned (1:1) to receive acupuncture (three sessions/week) plus topiramate placebo (acupuncture group) or topiramate (50-100 mg/day) plus sham acupuncture (topiramate group) over 12 weeks, with the primary outcome being the mean change in monthly migraine days during weeks 1-12.Results: Of 123 screened patients, 60 (mean age 45.8, 81.7% female) were randomly assigned to acupuncture or topiramate groups. Acupuncture demonstrated significantly greater reductions in monthly migraine days than topiramate (weeks 1-12: -2.79 [95% CI: -4.65 to -0.94, p = 0.004]; weeks 13-24: -3.25 [95% CI: -5.57 to -0.92, p = 0.007]). No severe adverse events were reported.Conclusions: Acupuncture may be safe and effective for treating chronic migraine. The efficacy of 12 weeks of acupuncture was sustained for 24 weeks and superior to that of topiramate. Acupuncture can be used as an optional preventive therapy for chronic migraine.Trial registration: ISRCTN.org Identifier 13563102.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 6","pages":"3331024241261080"},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation. 诱导 cGMP 介导的偏头痛发作与 CGRP 受体激活无关。

IF 5 2区医学

Cephalalgia Pub Date : 2024-06-01 DOI: 10.1177/03331024241259489

Bianca Raffaelli, Thien Phu Do, Håkan Ashina, Josefin Snellman, Tina Maio-Twofoot, Messoud Ashina

{"title":"Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation.","authors":"Bianca Raffaelli, Thien Phu Do, Håkan Ashina, Josefin Snellman, Tina Maio-Twofoot, Messoud Ashina","doi":"10.1177/03331024241259489","DOIUrl":"10.1177/03331024241259489","url":null,"abstract":"Background: The cAMP and cGMP pathways are implicated in the initiation of migraine attacks, but their interactions remain unclear. Calcitonin gene-related peptide (CGRP) triggers migraine attacks via cAMP, whereas the phosphodiesterase-5 inhibitor sildenafil induces migraine attacks via cGMP. Our objective was to investigate whether sildenafil could induce migraine attacks in individuals with migraine pre-treated with the CGRP-receptor antibody erenumab.Methods: In this randomized, double-blind, placebo-controlled, cross-over study, adults with migraine without aura received a single subcutaneous injection of 140 mg erenumab on day 1. They were then randomized to receive sildenafil 100 mg or placebo on two experimental days, each separated by at least one week, between days 8 and 21. The primary endpoint was the difference in the incidence of migraine attacks between sildenafil and placebo during the 12-h observation period after administration.Results: In total, 16 participants completed the study. Ten participants (63%) experienced a migraine attack within 12 h after sildenafil administration compared to three (19%) after placebo (p = 0.016). The median headache intensity was higher after sildenafil than after placebo (area under the curve (AUC) for the 12-h observation period, p = 0.026). Furthermore, sildenafil induced a significant decrease in mean arterial blood pressure (AUC, p = 0.026) and a simultaneous increase in heart rate (AUC, p < 0.001) during the first hour after administration compared to placebo.Conclusion: These findings provide evidence that migraine induction via the cGMP pathway can occur even under CGRP receptor blockade.Trial registration: ClinicalTrials.gov: Identifier NCT05889455.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 6","pages":"3331024241259489"},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141287852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transition of cluster headache: Depicting side-changing attacks as a chronic trait in an interview-based follow-up study. 丛集性头痛的转变：在一项基于访谈的随访研究中，将副变异性发作描述为一种慢性特征。

IF 5 2区医学

Cephalalgia Pub Date : 2024-06-01 DOI: 10.1177/03331024241258485

Marie-Louise Kulas Søborg, Anja Sofie Petersen, Nunu Lund, Mads Christian Johannes Barloese, Rigmor Højland Jensen

{"title":"Transition of cluster headache: Depicting side-changing attacks as a chronic trait in an interview-based follow-up study.","authors":"Marie-Louise Kulas Søborg, Anja Sofie Petersen, Nunu Lund, Mads Christian Johannes Barloese, Rigmor Højland Jensen","doi":"10.1177/03331024241258485","DOIUrl":"10.1177/03331024241258485","url":null,"abstract":"Background: Cluster headache presents in an episodic and chronic form, between which patients can convert during the course of disease. We aimed to quantify the rate of cluster headache patients changing phenotype within one and five years and investigate the earlier proposed association between chronification and having side-shifting attacks.Methods: In total, 430 cluster headache patients well-characterized according to current International Classification of Headache Disorders criteria, who were all participants in a prior transition-study, were re-interviewed in an observational, retrospective, cross-sectional follow-up study design at the Danish Headache Center.Results: The transition rate for the whole cohort was 6.5% within one year and 19.8% within five years. The risk of becoming chronic if episodic was 4.0% within one year and 12.3% within five years. For conversion from chronic to episodic, the corresponding risk was 11.1% and 25.0%, respectively. Alterations in attack-side were reported in 32% of all chronic patients, generating an odds ratio of 2.24 of being chronic as opposed to episodic if experiencing side-shifting attacks.Conclusions: A higher transition rate since the original cross-sectional study demonstrates cluster headache as a non-static condition. Identifying a risk of transition within one and five years, based on current phenotype along with high odds of being chronic when experiencing a shift of attack-side, offers a valuable clinical compass in the dialogue with the patient.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 6","pages":"3331024241258485"},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

It is a long way to the top if you wanna citations? 如果你想引用，通往山顶的路还很长？

IF 4.9 2区医学

Cephalalgia Pub Date : 2024-05-01 DOI: 10.1177/03331024241251487

David García-Azorín

引用次数: 0

What predicts citation counts and translational impact in headache research? A machine learning analysis 是什么预测了头痛研究的引用次数和转化影响？机器学习分析

IF 4.9 2区医学

Cephalalgia Pub Date : 2024-05-01 DOI: 10.1177/03331024241251488

Antonios Danelakis, Helge Langseth, Parashkev Nachev, Amy Nelson, Marte-Helene Bjørk, Manjit S. Matharu, Erling Tronvik, Arne May, Anker Stubberud

{"title":"What predicts citation counts and translational impact in headache research? A machine learning analysis","authors":"Antonios Danelakis, Helge Langseth, Parashkev Nachev, Amy Nelson, Marte-Helene Bjørk, Manjit S. Matharu, Erling Tronvik, Arne May, Anker Stubberud","doi":"10.1177/03331024241251488","DOIUrl":"https://doi.org/10.1177/03331024241251488","url":null,"abstract":"BackgroundWe aimed to develop the first machine learning models to predict citation counts and the translational impact, defined as inclusion in guidelines or policy documents, of headache research, and assess which factors are most predictive.MethodsBibliometric data and the titles, abstracts, and keywords from 8600 publications in three headache-oriented journals from their inception to 31 December 2017 were used. A series of machine learning models were implemented to predict three classes of 5-year citation count intervals (0–5, 6–14 and, >14 citations); and the translational impact of a publication. Models were evaluated out-of-sample with area under the receiver operating characteristics curve (AUC).ResultsThe top performing gradient boosting model predicted correct citation count class with an out-of-sample AUC of 0.81. Bibliometric data such as page count, number of references, first and last author citation counts and h-index were among the most important predictors. Prediction of translational impact worked optimally when including both bibliometric data and information from the title, abstract and keywords, reaching an out-of-sample AUC of 0.71 for the top performing random forest model.ConclusionCitation counts are best predicted by bibliometric data, while models incorporating both bibliometric data and publication content identifies the translational impact of headache research.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"84 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140830878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on ''Correlation between endometriosis and migraine features: Results from a prospective case-control study''. 关于 "子宫内膜异位症与偏头痛特征之间的相关性：一项前瞻性病例对照研究的结果 "发表评论。

IF 4.9 2区医学

Cephalalgia Pub Date : 2024-05-01 DOI: 10.1177/03331024241254824

Utku Akgor, Onur Ince

引用次数: 0

Migraine and risk of atrial fibrillation: A 9-year follow-up based on the Trøndelag Health Study. 偏头痛与心房颤动风险：基于特伦德拉格健康研究的 9 年随访。

IF 4.9 2区医学

Cephalalgia Pub Date : 2024-05-01 DOI: 10.1177/03331024241254517

Samita Giri, Erling Tronvik, Håvard Dalen, Hanne Ellekjær, Jan P Loennechen, Alexander Olsen, Knut Hagen

{"title":"Migraine and risk of atrial fibrillation: A 9-year follow-up based on the Trøndelag Health Study.","authors":"Samita Giri, Erling Tronvik, Håvard Dalen, Hanne Ellekjær, Jan P Loennechen, Alexander Olsen, Knut Hagen","doi":"10.1177/03331024241254517","DOIUrl":"https://doi.org/10.1177/03331024241254517","url":null,"abstract":"Background: Data from some population-based studies have indicated an increased risk of atrial fibrillation (AF) among patients with migraine, particularly among individuals with migraine with aura. The present study aimed to assess the association between primary headache disorders and AF.Methods: In a population-based 9-year follow-up design, we evaluated the questionnaire-based headache diagnosis, migraine and tension-type headache (TTH) included, collected in the Trøndelag Health Study (HUNT3) conducted in 2006-2008, and the subsequent risk of AF in the period until December 2015. The population at risk consisted of 39,340 individuals ≥20 years without AF at HUNT3 baseline who answered headache questionnaire during HUNT3. The prospective association was evaluated by multivariable Cox proportional hazard models with 95% confidence intervals (CIs).Results: Among the 39,340 participants, 1524 (3.8%) developed AF during the 9-year follow up, whereof 91% of these were ≥55 years. In the multivariable analyses, adjusting for known confounders, we did not find any association between migraine or TTH and risk of AF. The adjusted hazard ratios (HRs) were respectively 0.84 (95% CI = 0.64-1.11) for migraine, 1.16 (95% CI = 0.86-1.27) for TTH and 1.04 (95% CI = 0.86-1.27) for unclassified headache. However, in sensitivity analyses of individuals aged ≥55 years, a lower risk of AF was found for migraine (HR = 0.53; 95% CI = 0.39-0.73).Conclusions: In this large population-based study, no increased risk of AF was found among individuals with migraine or TTH at baseline. Indeed, among individuals aged ≥55 years, migraine was associated with a lower risk for AF.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 5","pages":"3331024241254517"},"PeriodicalIF":4.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141160941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition? 病例报告：偏头痛女性患者的性功能障碍可能是 CGRP 抑制剂的副作用吗？

IF 4.9 2区医学

Cephalalgia Pub Date : 2024-05-01 DOI: 10.1177/03331024241248837

Linda Al-Hassany, Deirdre M Boucherie, Emile G M Couturier, Antoinette MaassenVanDenBrink

{"title":"Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?","authors":"Linda Al-Hassany, Deirdre M Boucherie, Emile G M Couturier, Antoinette MaassenVanDenBrink","doi":"10.1177/03331024241248837","DOIUrl":"10.1177/03331024241248837","url":null,"abstract":"Background: The development and approval of antibodies targeting calcitonin gene-related peptide or its receptor mark a revolutionary era for preventive migraine treatment. Real-world evidence sheds light on rare, stigmatized or overlooked side effects of these drugs. One of these potential side effects is sexual dysfunction.Case reports: We present two cases of one 42-year-old and one 45-year-old female patient with chronic migraine who both reported sexual dysfunction as a possible side effect of treatment with galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide.Discussion: As calcitonin gene-related peptide is involved in vaginal lubrication as well as genital sensation and swelling, inhibiting the calcitonin gene-related peptide pathway may lead to sexual dysfunction as a potential side effect.Conclusion: Sexual dysfunction in female migraine patients might be a rare and overlooked side effect of monoclonal antibodies targeting the calcitonin gene-related peptide pathway. Considering the discomfort and stigma surrounding both migraine and sexual dysfunction, we advocate for an open attitude and awareness among clinicians toward such side effects.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 5","pages":"3331024241248837"},"PeriodicalIF":4.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0